Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Published byΑελλαι Αλιβιζάτος Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific."— Presentation transcript:

1 Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent.
In vivo tumor responses are mechanism of action–specific and concentration-dependent. (A and B) Ramos lymphoma tumors were injected with arrays containing a vehicle control, mafosfamide (MAF), doxorubicin (DOX), vincristine, and prednisolone (PRED), each delivered from a distinct needle within the array, and tumors were resected 24 hours later. Tissue sections from multiple depths along the injection column were stained with H&E or antibodies recognizing γH2AX, pHH3, or CC3. (A) Representative whole-section images from resected tumors. (B) Individual injection sites from tumors. (C) Ramos lymphoma tumors were microinjected with varying concentrations of each drug, each concentration through a distinct needle within the array, and tumors resected 24 and 72 hours after microinjection. Tissue sections were stained with antibodies recognizing γH2AX, pHH3, or CC3, and the fraction of biomarker-positive cells was plotted as a function of radial distance from the injection site. Data are average responses across multiple tumors ± SEM (mafosfamide, n = 5; doxorubicin, n = 15; vincristine, n = 8; and prednisolone, n = 4). Richard A. Klinghoffer et al., Sci Transl Med 2015;7:284ra58 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific."

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Fluorescence-based in vivo imaging of MSP.

Fluorescence-based in vivo imaging of MSP.
T2-weighted cross-sectional MR imaging of MSP swarms inside SD rats.

T2-weighted cross-sectional MR imaging of MSP swarms inside SD rats.
Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.
CD facilitates RCT in vivo and promotes urinary cholesterol excretion

CD facilitates RCT in vivo and promotes urinary cholesterol excretion
Fig. 3 CSF1 is expressed in human melanoma.

Fig. 3 CSF1 is expressed in human melanoma.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.
Biocompatibility evaluation in vivo with a mouse subcutaneous implant

Biocompatibility evaluation in vivo with a mouse subcutaneous implant
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 2 CFD results. CFD results. Results of CFD simulations in horizontal (left column) and vertical (right column) cross-sections. All models oriented.

Fig. 2 CFD results. CFD results. Results of CFD simulations in horizontal (left column) and vertical (right column) cross-sections. All models oriented.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.
T2-weighted cross-sectional MR imaging of MSP swarms inside SD rats.

T2-weighted cross-sectional MR imaging of MSP swarms inside SD rats.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Similar presentations

Ads by Google